Patent · US Active

Use of cannabinoids in the treatment of epilepsy

US10709671B2 · kind B2 · utility

45Cited by
20References
24Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 16, 2016
Grant dateJul 14, 2020
Priority date—
Expiry dateJun 16, 2036

Classification

  • Technology area (CPC B)Performing Operations; Transporting
  • CPC primaryB01D11/0288
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are children and young adults. CBD appears particularly effective in reducing focal seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities in comparison to other seizure types. Significantly CBD additionally is very effective in the reduction of a sub-type of focal seizures, focal seizures with impairment.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.